Emergency Department Visits and Deaths from Cardiovascular Diseases at a Referral Center for Cardiology During the COVID-19 Pandemic

Abstract

In December 2019, in the city of Wuhan, capital of Hubei Province, in China, the first cases of a new disease that would reach global proportions and become devastating in many aspects were identified. [1][2][3] The world has watched the spread of this disease caused by the new coronavirus (COVID-19) from Asia to Europe and then to the Americas in less than three months. On March 11, 2020, the World Health Organization (WHO) 1 announced the COVID-19 outbreak a pandemic.In addition to its rapid transmission, even by presymptomatic and asymptomatic infected individuals, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has significantly higher mortality as compared with other coronaviruses associated with

Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII)

“…[21][22][23][24][25] Além disso, vários estudos realizados no contexto epidemiológico e sanitário brasileiro relataram uma série de fatores de risco cardiovascular associados tanto à sobrecarga como ao prognóstico da COVID-19. [26][27][28][29] Foram realizados ensaios controlados randomizados de terapias antitrombóticas em pacientes com COVID-19 hospitalizados, especialmente em pacientes críticos em unidades de terapia intensiva. [30][31][32][33][34][35] De fato, as diretrizes atuais recomendam a profilaxia antitrombótica com heparina de baixo peso molecular (LMWH) ou heparina não fracionada (UFH) para pacientes hospitalizados.…”